CRANFORD, N.J., Jan. 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 743,496 shares of its common stock and accompanying warrants to purchase up to an aggregate of 743,496 shares of its common stock, at a purchase price of $4.035 per sha ...

Technology stocks were in fine form on the stock market in 2024, with the tech-laden Nasdaq Composite (^IXIC -1.89%) index clocking impressive gains of 28.6% last year following an even stronger jump of 43% in 2023.Historical trends indicate that the Nasdaq Composite could be on track to deliver more gains in 2025. In any year where the Nasdaq managed a 30%-plus gain overall, it averaged a 19% jump in the year that followed. Moreover, the Nasdaq averages a 17% return following a year in which it delivered r ...

MONTREAL and CHARLOTTE, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 113,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to employment of three new hires.  The Op ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

The Nasdaq Composite (^IXIC 1.24%) has been a great performing index, as it beat the broader S&P 500 (^GSPC 0.55%) in 2024 by rising 28.6% versus the S&P 500's 23.3%. It wouldn't surprise me to see those results again in 2025, but I think a few companies within the Nasdaq Composite can outperform the broader index in 2025.These stocks are Meta Platforms (META 4.23%), Alphabet (GOOG 2.50%) (GOOGL 2.65%), ASML (ASML 7.58%), PayPal (PYPL 2.20%), and MercadoLibre (MELI -1.90%). I think all five of these stocks ...

The CNN Money Fear and Greed index showed some easing in the overall fear level, while the index remained in the “Fear” zone on Monday.U.S. stocks settled mostly higher on Monday, with the S&P 500 and Nasdaq Composite recording back-to-back gains during the session.Chip stocks were among the top gainers of the session after Foxconn disclosed record revenue for the fourth quarter. Nvidia Corp. NVDA shares gained 3.4%, while Micron Technology Inc. MU jumped 10.5% on Monday.Among Monday's notable headlines, Th ...

STATEN ISLAND, N.Y., Jan. 6, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,463,058 shares of its common stock at a purchase price of $1.015 per share in a registered direct offering priced at-the-market under Nasdaq rules. In ...

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite jumping more than 200 points on Monday.The Dow traded up 0.08% to 42,765.84 while the NASDAQ gained 1.05% to 19,828.63. The S&P 500 also rose, gaining, 0.59% to 5,976.38.Check This Out: This Analyst With 85% Accuracy Rate Sees Around 16% Downside In Tesla – Here Are 5 Stock Picks For Last Week From Wall Street’s Most Accurate AnalystsLeading and Lagging SectorsInformation technology shares jumped by 2.1% on Monday.In trading on M ...

股价表现 - T-Mobile股价在周一早盘下跌4.3% 至219美元 而纳斯达克综合指数上涨1.8% [1] - 2024年T-Mobile股价累计上涨40% 包括股息 [1] 分析师评级 - 富国银行和RBC资本将T-Mobile评级从买入下调至持有 [2] - 富国银行将目标价从240美元下调至220美元 RBC将目标价从255美元下调至240美元 [2] 并购影响 - 2020年收购Sprint带来巨大成本协同效应 并在4G向5G过渡中获得频谱优势 [3] - 收购后T-Mobile市场份额持续增长 自由现金流大幅提升 [3] - 分析师认为并购带来的"低垂果实"已被摘取 [4] 财务指标 - T-Mobile远期EBITDA倍数为11倍 自由现金流倍数为15倍 [4] - 竞争对手Verizon和AT&T的远期EBITDA倍数分别为7倍和9-11倍 [4] - 随着税率恢复正常 T-Mobile自由现金流增长将放缓 [4] 公司前景 - 分析师认为T-Mobile仍是"最佳选择" 并持续进行股票回购 [5] - 2023年T-Mobile将股息提高35% 当前股息收益率为1.6% 仍有较大增长空间 [6] - 对于距离退休10年左右的投资者 T-Mobile是抗衰退的优质选择 未来有望提供丰厚股息收益 [6]

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...